Medical Marijuana Trials: Pre-empted by Politics
There has been a lot of debate on the therapeutic use of marijuana. There are currently 24 states that have legalized marijuana for medical use.
There has been a lot of debate on the therapeutic use of marijuana. There are currently 24 states that have legalized marijuana for medical use. Most recently, two states, Washington and Colorado, have legalised the drug for recreational use.
While there is literature that suggests benefits of marijuana for medicinal use, particularly in animal models, funding and approvals for therapeutic marijuana use in clinical trials is limited. For example, Dr. Sue Sisley, a psychiatrist at the University of Arizona, lost her job over a proposal to study marijuana on posttraumatic stress disorder patients.
In this article, Applied Clinical Trials’ Moe Alsumidaie talks to Donald Abrams, MD, Cancer and Integrative Medicine Specialist at the UCSF Osher Center for Integrative Medicine at Mount Zion, and Chief of Hematology and Oncology at San Francisco General Hospital, about his experience in running therapeutic marijuana clinical trials. Click here.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement
April 1st 2025The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to facilitate completion of the NEPHRO CRRT study of Niyad in patients undergoing renal replacement therapy by the end of 2025.
